Results 1 to 10 of about 1,979 (79)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination [PDF]

npj Vaccines, 2023
Gardasil® (Merck) and Cervarix® (GlaxoSmithKline) both provide protection against infection with Human Papillomavirus 16 (HPV16) and Human Papillomavirus 18 (HPV18), that account for around 70% of cervical cancers. Both vaccines have been shown to induce
Vicky Roy, Wonyeong Jung, Caitlyn Linde, Emily Coates, Julie Ledgerwood, Pamela Costner, Galina Yamshchikov, Hendrik Streeck, Boris Juelg, Douglas A. Lauffenburger, Galit Alter   +10 more
doaj   +2 more sources

Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9 [PDF]

Human Vaccines & Immunotherapeutics, 2019
High-risk human papillomavirus (HPV) types are responsible for nearly all cases of cervical cancers. Cervarix® and Gardasil® 9 are the current prophylactic vaccines available that protect against the majority of HPVs associated with cancer.
Nitesh K. Kunda, Julianne Peabody, Lukai Zhai, Dominique N. Price, Bryce Chackerian, Ebenezer Tumban, Pavan Muttil   +6 more
doaj   +2 more sources

Impact of HPV vaccination with Gardasil® in Switzerland [PDF]

BMC Infectious Diseases, 2017
Background Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomaviruses (HPV), has been offered to 11–14 year-old schoolgirls in Switzerland since 2008.
Martine Jacot-Guillarmod, Jérôme Pasquier, Gilbert Greub, Massimo Bongiovanni, Chahin Achtari, Roland Sahli   +5 more
doaj   +2 more sources

Gardasil® as adjunctive therapy for respiratory papillomatosis at Red Cross Children’s Hospital, Cape Town [PDF]

Journal of the Colleges of Medicine of South Africa
Background: Juvenile onset recurrent respiratory papillomatosis (JoRRP) is an incurable condition caused by human papilloma virus (HPV) types 6 and 11, often requiring repeated surgeries and in severe cases, tracheostomy.
Shavina Frank, Jessica K. McGuire, Fiona Kabagenyi, Vincent Pretorius, Shazia Peer   +4 more
doaj   +2 more sources

Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports [PDF]

Human Vaccines & Immunotherapeutics
Human papillomavirus (HPV) vaccination is central to preventing cervical and other HPV-associated cancers. Although clinical trials have established favorable safety profiles, long-term, brand-specific real-world data remain limited. We evaluated adverse
Yonglong Su, Yirong Huang, Jinbao Wei, Xinjin Wang, Yanyan Zhou, Xiaohong Wu, Honghong Fu   +6 more
doaj   +2 more sources

Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial [PDF]

npj Vaccines
Tanzanian girls received one to three doses of Gardasil®9 in the DoRIS randomised trial. Blood samples from one and two-dose Gardasil®9 recipients were collected at months (M)0, M7, M12, M24, and M36 for testing via an HPV Multiplex immunoassay.
Troy J. Kemp, Kathy Baisley, John Changalucha, Jackton Indangasi, Hilary Whitworth, Charles J. Lacey, David Mwanzalima, Ramadhan Hashim, Saidi Kapiga, Richard J. Hayes, Ligia A. Pinto, Deborah Watson-Jones   +11 more
doaj   +2 more sources

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. [PDF]

PLoS ONE, 2013
The current generation of Human Papillomavirus (HPV) vaccines, Cervarix® and Gardasil®, exhibit a high degree of efficacy in clinical trials against the two high-risk (HR) genotypes represented in the vaccines (HPV16 and HPV18).
Eve Draper, Sara L Bissett, Rebecca Howell-Jones, Pauline Waight, Kate Soldan, Mark Jit, Nicholas Andrews, Elizabeth Miller, Simon Beddows   +8 more
doaj   +2 more sources

Immunogenicity of an Escherichia coli-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats [PDF]

Vaccines
Background: Prophylactic human papillomavirus (HPV) vaccines are crucial for preventing HPV-related cancers. This study aimed to preclinically evaluate a novel recombinant 9-valent HPV vaccine produced in Escherichia coli (E.
Yu-Ying Liu, Fei Yin, Wen-Juan Li, Dan Chen, Shu-Ming Wu, Xiao Chen, Yan Wang, Zeng-Min Yang, Hai-Jiang Zhang, Yong-Jiang Liu   +9 more
doaj   +2 more sources

An engineered intradermal microneedle-array device enhances the cellular immune responses in a guinea pig model [PDF]

Frontiers in Immunology
IntroductionIntradermal (ID) vaccination can be highly immunogenic due to the density of antigen-presenting cells in the skin, but reliable ID delivery remains technically challenging.
Marie-Edith Nepveu-Traversy, George (Giorgi) Babuadze, Darlene Potterton, Marc-Antoine de La Vega, Ales Alajbegovic, Jacinthe Julien, Andrew Winterborn, Gary Kobinger, Gary Kobinger   +8 more
doaj   +2 more sources

Therapeutic Impact of Gardasil^® in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients [PDF]

Viruses
Background: Recurrent respiratory papillomatosis (RRP) is a rare, non-malignant disease caused by human papillomavirus (HPV) types 6 and 11. The condition primarily affects the larynx, potentially leading to life-threatening airway obstruction.
Jennifer Sieg, Asita Fazel, Elgar Susanne Quabius, Astrid Dempfle, Susanne Wiegand, Markus Hoffmann   +5 more
doaj   +2 more sources